Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
External factors such as protein partners can also
2020-02-21
External factors, such as protein partners, can also activate DUBs by either reinforcing the stimulatory effects of intramolecular factors or by other means. The intramolecular activation of the USP7 CD by its HUBL domain is allosterically potentiated by external factor GMP synthase (GMPS), which co
-
DGK is classified into the type II DGK subfamily
2020-02-21
DGKη is classified into the type II DGK subfamily [12], [13], [14], [15]. As described above, DGKη has the splice variants η1 and η2 [10]. DGKs η1 and η2 possess in common a pleckstrin homology domain at the N-terminus and a catalytic domain that is divided into two subdomains (catalytic subdomain-a
-
Dihydrofolate reductase DHFR is an excellent
2020-02-21
Dihydrofolate reductase (DHFR) is an excellent molecular target for this study because it has been and is currently studied by using different molecular modeling techniques [6], [7], [8], [9]. Kerrigan et al. have reported an interesting review about recent progress in molecular dynamics simulations
-
Dronedarone Our previous studies have demonstrated
2020-02-21
Our previous studies have demonstrated that the DDR2 discoidin domain fully contains the binding site(s) for the fibrillar collagens I and II (Leitinger, 2003, Leitinger et al., 2004). The binding site for collagen I was mapped to three spatially adjacent surface loops within the DDR2 discoidin doma
-
Lesinurad receptor In this study cell migration in response
2020-02-21
In this study, cell migration in response to LTD4 exhibited a typical bell-shaped dose-response curve with optimal activity at 10 nM. However, the effect of inhaled CysLTs on airway inflammatory cells in vivo has not been widely reported to date, therefore, the role of CysLTs in the development of a
-
Perturbation in the cytokine network
2020-02-21
Perturbation in the cytokine network is correlated with disruption of growth hormone and glucocorticoid (GC) homeostasis (Thissen and Verniers, 1997; Sahid El-Radhi et al., 2000; Waxman and Holloway, 2009; Zhao et al., 2014), with important physiological consequences because cytokines affect the reg
-
Leukotrienes themselves are implicated in the development of
2020-02-21
Leukotrienes themselves are implicated in the development of gastrointestinal ulcers, asthmas, and different inflammatory processes [18], [19]. It is noteworthy that COX isozymes and LOX share the same substrate arachidonic acid; therefore, inhibition of prostaglandins production by cyclooxygenase
-
Loxapine br GPCRs form heterotetramers In addition to homodi
2020-02-20
GPCRs form heterotetramers In addition to homodimers and heterodimers, for several family A receptor heteromers, experimental evidence supports the presence of higher order rearrangements as tetrameric structures, comprised of two different homodimers, each able to signal with its preferred G pr
-
br Conflicts of interest br
2020-02-20
Conflicts of interest Introduction Diacylglycerols (DAGs) and phosphatidic Gadodiamide (PA) play fundamental roles in biology as basic components of membranes, intermediates in lipid metabolism, and secondary messengers in cellular signaling (Carrasco and Merida, 2007, Fang et al., 2001). Cell
-
br Conflicts of interest br Acknowledgments Work in the
2020-02-20
Conflicts of interest Acknowledgments Work in the laboratory of SPS is funded by Council of Scientific and Industrial Research (CSIR) Network Project BSC-0111 (INDEPTH) and BSC-0112 (NanoSHE). We are thankful to Director, CSIR-IITR for his constant encouragement and support. We also acknowledg
-
br Diseases which have been treated with proteins
2020-02-20
Diseases which have been treated with proteins linked to HSA A number of therapeutic products conjugated to HSA have now been approved for clinical use (Table 2). For example, fatty AR-12 derivatives of human insulin bound to HSA have applications in the treatment of diabetes while paclitaxel-HSA
-
br Materials and methods br Results br Discussion For
2020-02-20
Materials and methods Results Discussion For many years, oral PDE5-Is have been prescribed as an on-demand regimen for treating ED. Several studies have reported on the efficacy and safety of such a regimen, with an overall efficacy rate of 60–70% [21]. However, many patients complain of a
-
The best characterized APC C substrates are recruited via va
2020-02-20
The best-characterized APC/C substrates are recruited via various linear motifs (e.g., D boxes, KEN boxes, and ABBA motifs) that serve as degrons, binding to distinct regions of the β-propeller domain of a coactivator (Figure 1, Figure 3B) (reviewed in [44]). In addition, D boxes also simultaneously
-
The interface between the E ligase
2020-02-20
The interface between the E3 ligase and the E2 enzyme can vary, and ZNF451 and SP-RING ligases stabilize this interaction via noncovalent binding to a scaffold SUMO (SUMOB) on the backside of the E2 (Cappadocia et al., 2015; Eisenhardt et al., 2015; Streich & Lima, 2016). By contrast, RanBP2 does no
-
We have compared the potency of a
2020-02-20
We have compared the potency of a series of DNA-directed alkylating agents, including N-mustard-acridine, N-mustard-quinoline, and N-mustard-quinazoline conjugates previously synthesized in our laboratory [7], [13], and currently used drugs (oxaliplatin, cisplatin, or 5-FU) for the treatment of CRC
15862 records 867/1058 page Previous Next First page 上5页 866867868869870 下5页 Last page